Regarding response to Narayanan et al’s “Adverse events in cemiplimab therapy for locally advanced or metastatic cSCC: A global propensity-matched retrospective cohort study” - 29/11/24
Doi : 10.1016/j.jaad.2024.10.059
Kyle C. Lauck, MD a, Deepika Narayanan, MD b, Stanislav N. Tolkachjov, MD a, b, c, d, ⁎ 
a Division of Dermatology, Baylor University Medical Center, Dallas, Texas
b Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas
c Epiphany Dermatology, Dallas, Texas
d Department of Dermatology, University of Texas at Southwestern, Dallas, Texas
∗Correspondence to: Stanislav N. Tolkachjov, MD, 1640 FM 544. Suite 100, Lewisville, TX 75056, 1640 FM 544. Suite 100LewisvilleTX75056
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Friday 29 November 2024
Key words : cutaneous oncology, drug safety, epidemiology, immunotherapy, squamous cell carcinoma
El texto completo de este artículo está disponible en PDF.
| Funding sources: None. |
|
| Patient consent: Patient consent was not required for this study due to the retrospective nature of the study from an unidentified database. |
|
| IRB approval status: Data accessible via TriNetX are presented in aggregate form and only contain anonymized data as per the deidentification standard defined by the US Health Insurance Portability and Accountability Act (HIPAA) in section §164,514(a). Given this study used only deidentified data and did not involve individually identifiable patient data, this study was exempt from institutional review board approval. |
© 2024
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?